Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab

Tal Brosh-Nissimov; Nir Ma'aravi; Daniel Leshin-Carmel; Yonatan Edel; Sharon Ben Barouch; Yafit Segman; Amos Cahan; Erez Barenboim

doi:10.1016/j.jmii.2023.09.004

Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab

Tal Brosh-Nissimov, Nir Ma'aravi, Daniel Leshin-Carmel, Yonatan Edel, Sharon Ben Barouch, Yafit Segman, Amos Cahan, Erez Barenboim

Samson Assuta Ashdod University Hospital

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PCR cycle-threshold values, and C-reactive protein levels. Eleven patients achieved complete clinical and virological resolution, while three showed partial responses. The study suggests a potential association between non-response and tixegavimab/cilgavimab neutralization. The findings underscore the need for tailored treatment approaches and further research on optimal strategies for managing persistent COVID-19, as well as the development of antivirals and variant-specific monoclonal antibodies.

Original language	English
Pages (from-to)	189-194
Number of pages	6
Journal	Journal of Microbiology, Immunology and Infection
Volume	57
Issue number	1
DOIs	https://doi.org/10.1016/j.jmii.2023.09.004
State	Published - 1 Feb 2024

Keywords

COVID-19
Immunocompromised
Nirmatrelvir
Remdesivir
Tixegavimab/cilgavimab

ASJC Scopus subject areas

Immunology and Allergy
General Immunology and Microbiology
Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jmii.2023.09.004

Cite this

Brosh-Nissimov, T., Ma'aravi, N., Leshin-Carmel, D., Edel, Y., Ben Barouch, S., Segman, Y., Cahan, A., & Barenboim, E. (2024). Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab. Journal of Microbiology, Immunology and Infection, 57(1), 189-194. https://doi.org/10.1016/j.jmii.2023.09.004

@article{e66a0dfbd8374a94963ef34084dff179,

title = "Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab",

abstract = "We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PCR cycle-threshold values, and C-reactive protein levels. Eleven patients achieved complete clinical and virological resolution, while three showed partial responses. The study suggests a potential association between non-response and tixegavimab/cilgavimab neutralization. The findings underscore the need for tailored treatment approaches and further research on optimal strategies for managing persistent COVID-19, as well as the development of antivirals and variant-specific monoclonal antibodies.",

keywords = "COVID-19, Immunocompromised, Nirmatrelvir, Remdesivir, Tixegavimab/cilgavimab",

author = "Tal Brosh-Nissimov and Nir Ma'aravi and Daniel Leshin-Carmel and Yonatan Edel and {Ben Barouch}, Sharon and Yafit Segman and Amos Cahan and Erez Barenboim",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2024",

month = feb,

day = "1",

doi = "10.1016/j.jmii.2023.09.004",

language = "English",

volume = "57",

pages = "189--194",

journal = "Journal of Microbiology, Immunology and Infection",

issn = "1684-1182",

publisher = "Elsevier Ltd.",

number = "1",

}

Brosh-Nissimov, T, Ma'aravi, N, Leshin-Carmel, D, Edel, Y, Ben Barouch, S, Segman, Y, Cahan, A & Barenboim, E 2024, 'Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab', Journal of Microbiology, Immunology and Infection, vol. 57, no. 1, pp. 189-194. https://doi.org/10.1016/j.jmii.2023.09.004

Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab. / Brosh-Nissimov, Tal; Ma'aravi, Nir; Leshin-Carmel, Daniel et al.
In: Journal of Microbiology, Immunology and Infection, Vol. 57, No. 1, 01.02.2024, p. 189-194.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab

AU - Brosh-Nissimov, Tal

AU - Ma'aravi, Nir

AU - Leshin-Carmel, Daniel

AU - Edel, Yonatan

AU - Ben Barouch, Sharon

AU - Segman, Yafit

AU - Cahan, Amos

AU - Barenboim, Erez

PY - 2024/2/1

Y1 - 2024/2/1

N2 - We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PCR cycle-threshold values, and C-reactive protein levels. Eleven patients achieved complete clinical and virological resolution, while three showed partial responses. The study suggests a potential association between non-response and tixegavimab/cilgavimab neutralization. The findings underscore the need for tailored treatment approaches and further research on optimal strategies for managing persistent COVID-19, as well as the development of antivirals and variant-specific monoclonal antibodies.

AB - We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PCR cycle-threshold values, and C-reactive protein levels. Eleven patients achieved complete clinical and virological resolution, while three showed partial responses. The study suggests a potential association between non-response and tixegavimab/cilgavimab neutralization. The findings underscore the need for tailored treatment approaches and further research on optimal strategies for managing persistent COVID-19, as well as the development of antivirals and variant-specific monoclonal antibodies.

KW - COVID-19

KW - Immunocompromised

KW - Nirmatrelvir

KW - Remdesivir

KW - Tixegavimab/cilgavimab

UR - http://www.scopus.com/inward/record.url?scp=85173160917&partnerID=8YFLogxK

U2 - 10.1016/j.jmii.2023.09.004

DO - 10.1016/j.jmii.2023.09.004

M3 - Article

C2 - 37805361

AN - SCOPUS:85173160917

SN - 1684-1182

VL - 57

SP - 189

EP - 194

JO - Journal of Microbiology, Immunology and Infection

JF - Journal of Microbiology, Immunology and Infection

IS - 1

ER -

Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this